PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Behav Sci Law. Author manuscript; available in PMC Feb 27, 2009.
Published in final edited form as:
PMCID: PMC2648970
NIHMSID: NIHMS76662
Gender Differences in Comorbid Disorders among Offenders in Prison Substance Abuse Treatment Programs
Caron Zlotnick, Ph.D.,* Jennifer G. Clarke, M.D., M.P.H., Peter D. Friedmann, M.D., M.P.H., Mary B. Roberts, M.S.,§ Stanley Sacks, Ph.D., and Gerald Melnick, Ph.D.††
Assistant Professor of Medicine, Brown University, Research Center for Primary Care and Prevention Memorial Hospital of RI
Associate Professor of Medicine, Brown University, Program to Integrate Psychosocial and Health Services
§Statistical Programmer, Research Center for Primary Care and Prevention Memorial Hospital of RI
Director, Center for the Integration of Research and Practice (CIRP), National Development and Research Institutes, Inc. (NDRI)
††Senior Principal Investigator, Center for the Integration of Research and Practice (CIRP), National Development and Research Institutes, Inc. (NDRI)
*Correspondence to: Caron Zlotnick, Ph.D., Associate Professor of Medicine, Brown University, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, U.S.A. E-mail: czlotnick/at/butler.org
This study examined gender differences in a range of lifetime psychiatric disorders in a sample of 272 offenders newly admitted to a prison substance abuse program. Although these men and women did not differ in severity of substance use in the six months prior to incarceration, women were significantly more likely than men to report a lifetime psychiatric disorder and a lifetime severe disorder. Furthermore, gender differences emerged in the pattern of lifetime psychiatric comorbidity. Women reported greater lifetime major depression, posttraumatic stress disorder, eating disorder, and borderline personality disorder; men were more likely than women to meet criteria for antisocial personality disorder. Additionally, female offenders were found to have a higher degree of internalizing disorders than male offenders, but there were no gender differences in degree of externalizing disorders. The study concluded that women offenders newly admitted to a prison substance abuse program present with a greater psychiatric vulnerability and a different pattern of psychiatric comorbidity than their male counterparts.
High rates of co-occurring substance use and psychiatric disorders have been found in studies of male (Swartz & Lurigio, 1999) and female offenders (Abram, Teplin, & McClelland, 2003). Few studies have examined gender differences in patterns of psychiatric comorbidity among substance-using offenders. Studies that have compared general psychopathology of incarcerated men and women in drug treatment programs have found that incarcerated women report more severe substance use histories, coexisting psychological problems, histories of childhood abuse (Messina, Burdon, Hagopian, & Prendergrast, 2006; Peters, Strozier, Murrin, & Kearns, 1997; Messina, Burdon, & Prendergrast, 2003) and psychiatric comorbidity prior to incarceration (Messina et al., 2006) than their male counterparts. To date, only two studies have directly compared gender differences in specific psychiatric disorders of offenders in prison drug treatment programs. Messina et al. (2003) used self-report measures of lifetime depression, anxiety, and psychosis, and found that women were significantly more likely to report ever experiencing these disorders than men. Langan and Pelissier (2001) assessed for lifetime major depressive disorder and antisocial personality disorder using the Diagnostic Interview Schedule, and found that women were more likely to have lifetime major depressive disorder but that men and women were equally likely to meet criteria for antisocial personality disorder.
In contrast to incarcerated substance users, research with clinical samples of substance users has found no differences between women and men in severity of substance use (e.g., Downey, Rosengren, & Donovan, 2003; Galen, Brower, Gillespie, & Zucker, 2000). In a review of studies of gender differences in psychiatric comorbidity in substance users (that included antisocial personality disorder, depression, anxiety in general, and posttraumatic stress disorder), Pelissier and Jones (2005) asserted that no definitive conclusions about gender difference in overall mental health difficulties or specific diagnoses in substance users can be made. Gender differences in terms of prevalence of mental health disorders and severity of substance use that exist within substance users in community treatment may not readily generalize to incarcerated substance users in treatment because pathways to substance use treatment entry, and possibly motivation for substance use, may vary between the two groups.
Virtually no studies have examined gender differences in a range of psychiatric disorders among substance-using offenders; understanding these gender differences has assessment and treatment implications for this population. Several authors have recommended “gender sensitive” treatment for substance-abusing women offenders because of their unique needs, including mental health (Alemagno, 2001; Haywood, Kravitz, Goldman, & Freeman, 2000; Koons, Burrow, Morash, & Bynum, 1997).
In order to address gaps in the literature, the current study examined gender differences in lifetime psychiatric disorders in offenders newly admitted to a prison substance abuse program. This study focused on disorders for which empirical evidence suggests gender differences might exist in substance-using offenders (i.e. major depressive disorder (Langan and Pelissier, 2001; Messina et al., 2003) and antisocial personality disorder (Langan and Pelissier, 2001)). Eating disorders and borderline personality disorder are also included, as research suggests that women have higher rates than men of these disorders in samples of substance-users in treatment (Grilo et al., 1998; Marlowe et al., 1995), but this remains untested in our target population. Since most studies of gender differences in the general community have found that women have higher prevalence rates of lifetime affective disorders and anxiety disorders (Kessler et al., 1994), we also explored these gender differences in our sample of substance-abusing offenders. Finally, we explored whether there were gender differences in degree of internalizing and externalizing disorders. Research suggests that gender differences encompass these two major types of psychopathology: internalizing disorders, including anxiety and depression, which are more prevalent in females than in males; and externalizing disorders, including antisocial behavior, in which males predominate (Rosenfield, 2000).
The data for this study are from a larger study that aimed to validate the cut-off points for a mental health screening instrument (Co-Occurring Disorder Screening Instrument for Mental Disorders) for co-occurring disorders in offenders in prison substance abuse treatment programs (Sacks et al., 2007).
Participants
The study employed a geographically diverse sample of 280 consecutive new admissions to prison substance abuse treatment programs. A study subject was considered to be a “new admission” for 14 days from his/her entry to the treatment program. Exceptions were made under special circumstances; e.g., potential subjects were missed when a lockdown prevented interviews from being scheduled so that the initial test battery could not be completed within two weeks of entry to the program.
Four CJDATS (Criminal Justice Drug Abuse Treatment Studies) research centers were involved in the data collection and 13 different prison substance abuse treatment programs were used. The participating centers and the numbers of subjects drawn from each were NDRI Rocky Mountain in Colorado (N = 117), Lifespan at Brown University in Rhode Island (N = 75), the Institute for Behavioral Research at Texas Christian University in Texas (N = 60), and the Integrated Substance Abuse Programs at UCLA in California (N = 28). In order to have a sufficient number of women in the original study, the sample was stratified to include one-third women, which represented an over-sampling compared with the actual percentage of women in state prison populations (7%; Harrison & Beck, 2005). In addition to the 280 subjects who constituted the full sample, 29 (9%) refused to participate in the study and a communication barrier prevented two inmates (0.6%) from participating. The two inmates who reported a problem understanding the questions were replaced by the next subjects to enter the treatment program. Of the remaining 280 cases, eight had missing information on one or more of the diagnoses of interest in this study and were excluded from analyses. Thus, the total sample size for this analysis was 272.
Procedure
The study was approved by the institutional review boards at each of the four research centers, and each received certification from the Office for Human Research Protections (OHRP). The project was also approved by a data safety monitoring board and received a certificate of confidentiality from NIDA. The consent process was free from any coercion; participation was entirely voluntary and had no bearing on the inmate's circumstances, either within the treatment program or as a prisoner.
All measures were administered orally to avoid issues related to literacy in this population. Testing was conducted in two face-to-face sessions within one month of each other. The first session consisted of completing the informed consent and all other measures, besides the SCID. The second session was the administration of the SCID.
Measures
A modified (shorter version) of the structured CJDATS Intake Interview (Sacks et al., 2007) was administered to collect socio-demographic background including education and employment, criminal history, health and psychological status, and drug history. The Structured Clinical Interview for DSM-IV (SCID; First, Spitzer, Gibbon, & Williams, 2002) was used to measure lifetime mental disorders. The SCID is widely accepted as the “gold standard” for psychiatric disorders (Baldassano, 2005; Blackburn, 2000; Ramirez Basco et al., 2000; Magruder, Sonne, Brady, Quello, & Martin, 2005; Maffei et al., 1997). Interviewers trained and experienced in the use of the SCID administered the diagnostic interview. All the SCID interviews were reviewed by a SCID supervisor for completeness and accuracy.
To measure severity of substance use in the last six months prior to incarceration, the Texas Christian University Drug Screen (TCUDS; 19 items) was administered (Broome, Knight, Joe, & Simpson, 1996; Simpson, Joe, Rowan-Szal, & Greener, 1997). The TCUDS, designed to screen for alcohol and drug disorders, has been found to be highly effective and reliable over time in identifying substance use disorders in a sample of inmates (Peters, Greenbaum, Steinberg, & Carter, 2000).
The Internal Disorder Screener (IDS; 43 items, alpha of .96) and External Disorder Screener (EDS; 33 items, alpha of .96) subscales of the 15-item Global Appraisal of Individual Needs Short Screener Version 1.0 (GSS; Dennis, Chan, & Funk, 2006) was used to measure lifetime internalizing and externalizing disorders. Endorsement of one or more symptoms of the IDS has been used to identify over 95% of people with depression, anxiety, suicide ideation, acute/post-traumatic disorders, or other internal disorders. Likewise, one or more symptoms of the EDS has been used to identify over 95% of people with attention deficit, hyperactivity, other impulse control disorders, conduct disorder (including antisocial personality disorder), aggression or violence, criminal activity, or other external behavior problems.
Statistical Methods
Descriptive statistics were initially generated for the sample to examine gender differences and t-tests were used to determine significant differences by gender in continuous variables. Crosstabs with Pearson chi-square significance tests were used for gender differences in categorical variables. Multiple logistic regression and analysis of covariance were used to examine outcomes of interest while controlling for important covariates/confounders. Adjusted models included research center, participant gender (male/female), employment status (yes/no), marital status (never/ever), and a combined race/ethnicity variable (African American/Hispanic/Caucasian/other). All analyses were conducted with SPSS Version 11.0 (SPSS Inc., Chicago, IL) and SAS Version 9.1.3 (SAS Institute Inc., Cary, NC).
Demographic Profiles and Psychosocial Dysfunction
Most participants were men (66%). Males and females were similar on demographic variables: median age was 34, approximately one-third graduated from high school, and participants had an average of two minor children (Table 1). Lifetime cocaine use was the most commonly reported drug of use, followed by lifetime heroin use. Women were less likely to be Hispanic, to report daily alcohol use in the past six months, be employed in the past six months, and to have committed lifetime assault than men. Women compared to men were more likely in the past six months to report injection drug use and be homeless, and were more likely to report lifetime psychiatric hospitalization and suicide thoughts, feelings or attempts.
Table 1
Table 1
Demographics and psychosocial dysfunction of male and female offenders in a prison substance abuse program (N= 272)
Psychiatric Disorders
Women were significantly more likely than men to have a lifetime psychiatric disorder, after adjusting for race, marital status, employment status and research center (Table 2). Women were 18 times more likely to have an eating disorder and between 2.2 and 3.3 times more likely than men to have major depression, PTSD, borderline personality disorder, or any affective, anxiety, or psychotic disorder. Antisocial personality disorder was the only psychiatric disorder that women were less likely to report than men (adjusted OR 0.5). Examining only lifetime severe disorders (major depression, psychotic disorders and bipolar disorder), 46.7% of women were affected by one or more disorder compared with 24.7% of men (adjusted OR 2.7).
Table 2
Table 2
Odds ratio of psychiatric diagnosis by gender
Men and women had similar mean TCUDS scores (4.46 and 4.59 respectively, p = 0.232), indicating similar levels of drug dependence. As shown in Table 3, there was no difference in Externalizing Disorder Screen (EDS) scores by gender, but adjusted Internalizing Disorder Screen (IDS) scores were much higher for women than men (3.22 versus 2.31; p < 0.0001).
Table 3
Table 3
Substance abuse severity1, lifetime internalizing disorder2, and lifetime externalizing disorder3 by gender
The present study confirmed the findings of other studies (Messina et al., 2003, 2006; Peters et al., 1997) that women offenders in a prison substance abuse treatment have more lifetime mental health difficulties than their male counterparts. The present study expanded upon these findings in that it examined gender differences in a range of lifetime psychiatric disorders and associated lifetime DSM-IV psychopathology. In a sample of offenders newly admitted to various types of prison substance abuse treatment, women were significantly more likely than men to report a lifetime psychiatric disorder, affective disorder, anxiety disorder, and severe psychiatric disorder. Furthermore, women reported greater lifetime major depression, PTSD, eating disorder, and borderline personality disorder. Men in this sample were twice as likely to meet criteria for antisocial personality disorder.
Compared with women in the community, the women in this study were nearly twice as likely to have any affective disorder, a major depressive disorder (Kessler et al., 1994), or PTSD (Kessler et al., 1995), and have a greater likelihood of borderline personality disorder (Torgersen, Kringlen, & Cramer, 2001). Since these disorders have been associated with sexual and physical abuse (Molnar, Buka, & Kessler, 2001; Trull, Sher, Minks-Brown, Durbin, & Burr, 2000) and past studies have reported higher rates of these traumas among incarcerated women than incarcerated males (Langan & Pelissier, 2001; Messina et al., 2003), perhaps an abuse history increases the vulnerability of female offenders with substance use to psychiatric comorbidity. A model that has been proposed to understand the link between childhood abuse, psychopathology, and substance use is the self-medication model. It has been postulated that childhood abuse disrupts the development of affect-regulation skills, which predisposes an individual towards developing psychopathology, such as PTSD, depression, and borderline personality disorder. Substances are then used in an attempt to medicate the profound symptoms of these disorders (Epstein, Saunders, Kilpatrick, & Resnick, 1998; Herman, 1992; Zlotnick et al., 2006). A treatment that focuses on affect management skills, such as Dialectical Behavior Therapy, which has been found to be an efficacious treatment for women with drug dependence and borderline personality disorder (Linehan et al., 1999), might be beneficial to female incarcerated substance users with comorbid disorders associated with childhood sexual abuse.
The only disorder for which men were more likely to meet criteria than women was antisocial personality disorder. Another study of offenders in a prison substance use program found no gender differences for this disorder (Langan & Pelissier, 2001). This latter study used a sample of federal prisoners whereas the current study used a sample of state prisoners. Differences between the studies' samples may account for the divergent results. Also, our finding that men were significantly more likely to have committed assault than women may have contributed to the relatively high proportion of men with a diagnosis of antisocial personality disorder.
The gender difference in degree of internalizing disorders in the current study is consistent with the finding that more women than men reported lifetime major depression, PTSD, and suicidality, given that the internalizing disorder subscale of the GSS includes both depression, anxiety disorder, traumatic distress, and suicide. The finding of a higher degree of internalizing disorders in women suggests that incarcerated women, despite their criminal behavior, tend to have a similar profile in terms of psychiatric morbidity to women in the community, who have also been found to report more internalizing psychopathology than their male counterparts (Rosenfield, 2000). It is possible, however, that the gender differences found in this study (and other studies) reflect women's greater willingness to self-disclose symptoms, especially those related to the internalizing disorders of depression, anxiety, and traumatic stress.
Unlike women in the community, men in our study did not report a higher degree of externalizing behaviors than women. Since externalizing behaviors are highly related to substance use severity (Dennis et al., 2006) and our study did not find gender differences in substance use severity, perhaps substance abuse severity accounted for the lack of gender differences in externalizing behaviors. Also, the externalizing subscale scale of the GSS taps symptoms related to attention deficit and hyperactivity/impulsivity: disorders that are likely to be more prevalent among incarcerated women than women in the general community.
In contrast to most other studies with drug-involved prisoners (e.g. Messina et al., 2003; Peters et al., 1997), the current study found no significant gender differences in recent (within the last six months) severity of substance use or in type of drug used, except that women in our study were more likely to report intravenous drug use. Obvious differences in study findings may be attributable to different designs, including different measures of severity of substance use, as well as different time periods in which studies were conducted, which may be associated with different patterns of drug use. Nevertheless, the fact that there was a gender difference in lifetime intravenous drug use, not measured by other studies, suggests that incarcerated women in prison substance use treatment programs have engaged in more serious drug use than their male counterparts prior to incarceration.
Limitations of this study include the cross-sectional design of the study, which precludes the study from addressing important issues concerning the temporal relationship between substance use disorder and comorbid psychiatric disorders. Research in the general community suggests that individuals with comorbid disorders tend to report that their first mental disorder occurred at an earlier age than their first substance disorder (Kessler, 2004). Longitudinal, prospective studies will contribute to our understanding of how substance use among incarcerated women is related to psychiatric impairment. Another limitation of this study is that it did not differentiate current from past psychiatric disorders, as there was limited power to detect differences due to the low number of cases for many of the psychiatric disorders of interest. Finally, the findings derive from prisoners who chose to participate in a prison substance use program and may not generalize to other prison populations.
Despite these limitations, this study concludes that women offenders who enter various types of prison substance use program present with greater psychiatric vulnerability and a different pattern of psychiatric comorbidity than their male counterparts. This finding highlights the importance of comprehensive psychiatric evaluations for inmates entering a substance abuse prison program, especially for women. The gender difference in psychiatric comorbidity found in this study also suggests the need for gender-specific treatment. Many women in prison substance abuse treatment must address two distressing and often interactive disorders. Future research is needed to address the etiological, therapeutic, and organizational implications of gender differences in psychiatric comorbidity among offenders in a prison substance abuse treatment.
  • Abram KM, Teplin LA, McClelland GM. Comorbidity of severe psychiatric disorders and substance use disorders among women in jail. American Journal of Psychiatry. 2003;160:1007–1010. [PubMed]
  • Alemagno SA. Women in jail: Is substance abuse treatment enough? American Journal of Public Health. 2001;91(5):798–800. [PubMed]
  • Baldassano CF. Assessment tools for screening and monitoring bipolar disorder. Bipolar Disorders. 2005;7(1):8–15. [PubMed]
  • Blackburn R. Classification and assessment of personality disorders in mentally disordered offenders: A psychological perspective. Criminal Behaviour and Mental Health. 2000;10:S8–S33.
  • Broome KM, Knight K, Joe GW, Simpson DD. Evaluating the drug-abusing probationer: Clinical interview versus self-administered assessment. Criminal Justice and Behavior. 1996;23(4):593–606.
  • Dennis ML, Chan Y-F, Funk RR. Development and validation of the GAIN short screener (GSS) for internalizing, externalizing and substance use disorders and crime/violence problems among adolescents and adults. The American Journal on Addictions. 2006;15:80–91. [PubMed]
  • Downey L, Rosengren DB, Donovan DM. Gender, waitlists, and outcomes for public-sector drug treatment. Journal of Substance Abuse Treatment. 2003;25:19–28. [PubMed]
  • Epstein J, Saunders B, Kilpatrick D, Resnick H. PSTD as a mediator between childhood rape and alcohol use in adult women. Child Abuse and Neglect. 1998;22:223–234. [PubMed]
  • First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) Biometrics Research, New York State Psychiatric Institute; New York: 2002.
  • Galen LW, Brower KJ, Gillespie BW, Zucker RA. Sociopathy, gender and treatment outcome among outpatient substance abusers. Drug and Alcohol Dependence. 2000;61:23–33. [PubMed]
  • Grilo CM, Becker DF, Fehon DC, Walker ML, Edell WS, McGlashan TH. Psychiatric morbidity in male and female adolescent inpatients with alcohol use disorders. Journal of Youth and Adolescence. 1998;27(1):29–41.
  • Harrison PM, Beck AJ. Prisoners in 2004. Bureau of Justice Statistics Bulletin. 2005. October 2005, NCJ 210677. Retrieved November 1, 2006, from Office of Justice Programs website: http://www.ojp.usdoj.gov/bjs/pub/pdf/p04.pdf.
  • Haywood TW, Kravitz HM, Goldman LB, Freeman A. Characteristics of women in jail and treatment orientations. A. review. Behavior Modification. 2000;24(3):307–324. [PubMed]
  • Herman J. Trauma and recovery. Basic; New York: 1992.
  • Kessler RC. Impact of substance abuse on the diagnosis, course and treatment of mood disorders: The epidemiology of dual diagnosis. Biological Psychiatry. 2004;56:730–737. [PubMed]
  • Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51:8–19. [PubMed]
  • Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry. 1995;52:1048–1060. [PubMed]
  • Koons B, Burrow J, Morash M, Bynum T. Expert and offender perceptions of program elements linked to successful outcomes for incarcerated women. Crime and Delinquency. 1997;43:512.
  • Langan NP, Pelissier BMM. Gender differences among prisoners in drug treatment. Journal of Substance Abuse. 2001;13:291–301. [PubMed]
  • Linehan MM, Schmidt H, Dimeff LA, Craft C, Kanter J, Comtois K. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. The American Journal on Addictions. 1999;8:279–292. [PubMed]
  • Maffei C, Fossati A, Agostonid I, Barraco A, Bagnato M, Deborah D, et al. Interrater reliability and internal consistency of the Structured Clinical Interview for DSM-IV Axis II personality disorders (SCID-II), Version 2.0. Journal of Personality Disorders. 1997;11(3):279–284. [PubMed]
  • Magruder KM, Sonne SC, Brady KT, Quello S, Martin RH. Screening for co-occurring mental disorders in drug treatment populations. Journal of Drug Issues. 2005;193:658–664.
  • Marlowe DB, Husband SD, Lamb RJ, Kirby KC, Iguchi MY, Platt JJ. Psychiatric comorbidity in cocaine dependence: Diverging trends, Axis II spectrum, and gender differentials. The American Academy of Psychiatrists in Alcoholism and Addictions. 1995;4(1):70–81.
  • Messina NP, Burdon WM, Hagopian G, Prendergast ML. Predictors of prison-based treatment outcomes: A comparison of men and women participants. The American Journal of Drug and Alcohol Abuse. 2006;32:7–28. [PubMed]
  • Messina NP, Burdon WM, Prendergast ML. Assessing the needs of women in institutional therapeutic communities. Journal of Offender Rehabilitation. 2003;37(2):89–106.
  • Molnar BE, Buka SL, Kessler RC. Child sexual abuse and subsequent psychopathology: Results from the National Comorbidity Survey. American Journal of Public Health. 2001;91(5):753–760. [PubMed]
  • Pelissier B, Jones N. A. review of gender differences among substance abusers. Crime and Delinquency. 2005;51:343–372.
  • Peters RH, Greenbaum PE, Steinberg ML, Carter CR. Effectiveness of screening instruments in detecting substance use disorders among prisoners. Journal of Substance Abuse Treatment. 2000;18(4):349–358. [PubMed]
  • Peters RH, Strozier AL, Murrin MR, Kearns WD. Treatment of substance-abusing jail inmates: Examination of gender differences. Journal of Substance Abuse Treatment. 1997;14(4):339–349. [PubMed]
  • Ramirez Basco. MR, Bostic JQ, Davies D, Rush AJ, Witte B, Hendrickse W, et al. Methods to improve diagnostic accuracy in a community mental health setting. American Journal of Psychiatry. 2000;157(10):1599–1605. [PubMed]
  • Rosenfield S. Gender and dimensions of the self: Implications for internalizing and externalizing behavior. In: Frank E, editor. Gender and its Effects on Psychopathology. American Psychiatric; Arlington, VA: 2000. pp. 23–36.
  • Sacks S, Melnick G, Coen C, Banks S, Friedmann PD, Grella C, Knight K, Zlotnick C. CJDATS Co-occurring disorders. Screening instrument (CODSI) for mental disorders (MD): A validation study. Criminal Justice and Behavior. 2007;34(9):1198–1215. [PMC free article] [PubMed]
  • Simpson DD, Joe GW, Rowan-Szal GA, Greener JM. Drug abuse treatment process components that improve retention. Journal of Substance Abuse Treatment. 1997;14(6):565–572. [PubMed]
  • Swartz JA, Lurigio AJ. Psychiatric illness and comorbidity among adult male jail detainees in drug treatment. Psychiatric Services. 1999;50:1628–1630. [PubMed]
  • Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Archives of General Psychiatry. 2001;58(6):590–596. [PubMed]
  • Trull TJ, Sher KJ, Minks-Brown C, Durbin J, Burr R. Borderline personality disorder and substance use disorders: A review and integration. Clinical Psychology Review. 2000;20(2):235–253. [PubMed]
  • Zlotnick C, Johnson DM, Stout RL, Johnson JE, Zywiak WH, Schneider RJ. Childhood abuse and intake severity in alcohol disorder patients. Journal of Traumatic Stress Disor der. 2006;19(6):949–959. [PubMed]